Carvedilol as a potential novel agent for the treatment of Alzheimer's disease

Neurobiology of Aging

Volumn 32, Issue 12, 2011, Pages 2321.e1-2321.e12

  Wang, Jun ^a   Ono, Kenjiro ^b   Dickstein, Dara L ^a   Arrieta Cruz, Isabel ^a   Zhao, Wei ^a   Qian, Xianjuan ^a   Lamparello, Ashley ^a   Subnani, Rakesh ^a   Ferruzzi, Mario ^c   Pavlides, Constantine ^d   Ho, Lap ^a,e   Hof, Patrick R ^a   Teplow, David B ^b   Pasinetti, Giulio M ^a,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PURDUE UNIVERSITY   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Basal neuronal transmission; Bioavailability; Cognitive function; Dendritic spine; Oligomeric A ; Spatial memory; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CARVEDILOL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CIRCULAR DICHROISM; CONTROLLED STUDY; DENDRITIC SPINE; ELECTRON MICROSCOPY; FEMALE; LONG TERM MEMORY; MEMORY CONSOLIDATION; MENTAL DETERIORATION; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN SECONDARY STRUCTURE; RECOGNITION; SPATIAL MEMORY; SYNAPTIC TRANSMISSION;

EID: 80053636250     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.05.004     Document Type: Article

References (56)

1. 11C] carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol 2005, 145:1045-1051.
2. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study "recognition memory". Nat. Protoc 2006, 1:1306-1311.
3. Bitan G., Lomakin A., Teplow D.B. Amyloid beta-Protein Oligomerization. Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem 2001, 276:35176-35184.
4. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein. J. Biol. Chem 2001, 695:276. 21562-21570.
5. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat. Neurosci 2005, 8:79-84.
6. Coleman P., Federoff H., Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004, 63:1155-1162.
7. Dandona P., Ghanim H., Brooks D.P. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens 2007, 25:731-741.
8. Duan H., Wearne S.L., Morrison J.H., Hof P.R. Quantitative analysis of the dendritic morphology of corticocortical projection neurons in the macaque monkey association cortex. Neuroscience 2002, 114:349-359.
9. Duan H., Wearne S.L., Rocher A.B., Macedo A., Morrison J.H., Hof P.R. Age-related Dendritic and Spine Changes in Corticocortically Projecting Neurons in Macaque Monkeys. Cereb. Cortex 2003, 13:950-961.
10. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats1: Behavioral data. Behav. Brain Res 1988, 31:47-59.
11. Gliebus G., Lippa C.F. The Influence of Beta-blockers on Delayed Memory Function in People With Cognitive Impairment. Am. J. Alzheimers Dis. Other Demen 2007, 22:57-61.
12. Goyagi T., Kimura T., Nishikawa T., Tobe Y., Masaki Y. Beta-adrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats. Anesth. Analg 2006, 103:658-663.
13. Gylys K.H., Fein J.A., Tan A.M., Cole G.M. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J. Neurochem 2003, 84:1442-1451.
14. Hao J., Rapp P.R., Leffler A.E., Leffler S.R., Janssen W.G., Lou W., McKay H., Roberts J.A., Wearne S.L., Hof P.R., Morrison J.H. Estrogen Alters Spine Number and Morphology in Prefrontal Cortex of Aged Female Rhesus Monkeys. J. Neurosci 2006, 26:2571-2578.
15. Harris K.M., Jensen F.E., Tsao B. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J. Neurosci 1992, 12:2685-2705.
16. Hayashi T., Saitou Y., Nose K., Nishioka T., Ishii T., Uemura H. Efficacy of Carvedilol for Ischemia/Reperfusion-Induced Oxidative Renal Injury in Rats. Transplant. Proc 2008, 40:2139-2141.
17. Holtmaat A.J., Trachtenberg J.T., Wilbrecht L., Shepherd G.M., Zhang X., Knott G.W., Svoboda K. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 2005, 45:279-291.
18. Howlett D.R., George A.R., Owen D.E., Ward R.V., Markwell R.E. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem. J 1999, 343:419-423.
19. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science 1996, 274:99-103.
20. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 2006, 103:5161-5166.
21. Jolas T., Zhang X.S., Zhang Q., Wong G., Vecchio R.D., Gold L., Priestley T. Long-Term Potentiation Is Increased in the CA1 Area of the Hippocampus of APPswe/ind CRND8 Mice. Neurobiol. Dis 2002, 11:394-409.
22. Kasai H., Matsuzaki M., Noguchi J., Yasumatsu N., Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci 2003, 26:360-368.
23. Kenton L., Boon F., Cain D.P. Combined but not Individual Administration of [beta]-Adrenergic and Serotonergic Antagonists Impairs Water Maze Acquisition in the Rat. Neuropsychopharmacology 2007, 33:1298-1311.
24. Kirkitadze M.D., Condron M.M., Teplow D.B. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol 2001, 312:1103-1119.
25. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int 2002, 41:345-352.
26. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L.Y., Anwyl R., Selkoe D.J., Rowan M.J. Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat. Med 2005, 11:556-561.
27. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci 2002, 22:6331-6335.
28. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers. J. Neurosci 2004, 24:10191-10200.
29. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A 1998, 95:6448-6453.
30. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
31. Lyketsos C.G., Reichman W.E., Paul K., Zhu Young Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease. Am. J. Geriatr. Psychiatry 2004, 12:473-482.
32. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., St.George-Hyslop P. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med 2006, 12:801-808.
33. Morris R. Developments of a water-maze procedure for studying spatial-learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
34. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J. Med 1996, 334:1349-1355. The U.S. Carvedilol Heart Failure Study Group.
35. Perez-Stable E.J., Coates T.J., Halliday R., Gardiner P.S., Hauck W.W. The effects of mild diastolic hypertension on the results of tests of cognitive function in adults 22 to 59 years of age. J. Gen. Intern. Med 1992, 7:19-25.
36. Peters A., Kaiserman-Abramof I.R. The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. Am. J. Anat 1970, 127:321-355.
37. Radley J.J., Rocher A.B., Miller M., Janssen W.G., Liston C., Hof P.R., McEwen B.S., Morrison J.H. Repeated Stress Induces Dendritic Spine Loss in the Rat Medial Prefrontal Cortex. Cereb. Cortex 2006, 16:313-320.
38. Rodriguez A., Ehlenberger D., Kelliher K., Einstein M., Henderson S.C., Morrison J.H., Hof P.R., Wearne S.L. Automated reconstruction of three-dimensional neuronal morphology from laser scanning microscopy images. Methods 2003, 30:94-105.
39. Rodriguez A., Ehlenberger D.B., Hof P.R., Wearne S.L. Rayburst sampling, an algorithm for automated three-dimensional shape analysis from laser scanning microscopy images. Nat. Protoc 2006, 1:2152-2161.
40. Rosenberg P.B., Mielke M.M., Tschanz J., Cook L., Corcoran C., Hayden K.M., Norton M., Rabins P.V., Green R.C., Welsh-Bohmer K.A., Breitner J.C., Munger R., Lyketsos C.G. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am. J. Geriatr. Psychiatry 2008, 16:883-892.
41. Rowan M.J., Klyubin I., Wang Q., Anwyl R. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem. Soc. Trans 2005, 33:563-567.
42. Saber A.J., Cain D.P. Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. Neuropsychopharmacology 2003, 28:1247-1256.
43. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobioil. Aging 2003, 24:1029-1046.
44. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., Lemere C.A. Dendrimeric A[beta] 1-15 is an effective immunogen in wild type and APP-tg mice. Neurobiol. Aging 2007, 28:813-823.
45. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
46. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. J. Neurosci 2007, 27:2866-2875.
47. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med 2008, 14:837-842.
48. Sholl A., Uttley A.M. Pattern discrimination and the visual cortex. Nature 2009, 171:387-388.
49. Terry R.D., Masliah E., Salmon D.P., Butters N., Deteresa R., Hill R., Hansen L.A., Katzman R. Physical Basis of Cognitive Alterations in Alzheimers-Disease - Synapse Loss Is the Major Correlate of Cognitive Impairment. Ann. Neurol 1991, 30:572-580.
50. Vollers S.S., Teplow D.B., Bitan G. Determination of Peptide oligomerization state using rapid photochemical crosslinking. Methods Mol. Biol 2005, 299:11-18.
51. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid [beta] protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
52. Wang J., Ho L., Chen L., Zhao Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., Pasinetti G.M. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest 2007, 117:3393-3402.
53. Wang J., Ho L., Qin W., Rocher A.B., Seror I., Humala N., Maniar K., Dolios G., Wang R., Hof P.R., Pasinetti G.M. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 2005, 19:659-661.
54. Wang J., Ho L., Zhao W., Ono K., Rosensweig C., Chen L., Humala N., Teplow D.B., Pasinetti G.M. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci 2008, 28:6388-6392.
55. Zhao W., Wang J., Ho L., Ono K., Teplow D.B., Pasinetti G.M. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J. Alzheimers Disord 2009, 16:49-57.
56. Zuo Y., Lin A., Chang P., Gan W.B. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron 2005, 46:181-189.